22 February 2018   
EMA/86370/2018  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Xgeva 
denosumab 
On 22 February 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Xgeva. The marketing authorisation holder for this medicinal product is Amgen Europe B.V. 
The CHMP adopted an extension to an existing indication as follows 2: 
“Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord 
compression or surgery to bone) in adults with bone metastases from solid tumours advanced 
malignancies involving bone (see section 5.1).” 
For information, the full indications for Xgeva will be as follows: 
“Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord 
compression or surgery to bone) in adults with advanced malignancies involving bone (see 
section 5.1). 
Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is 
unresectable or where surgical resection is likely to result in severe morbidity.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
                                                
